Remdesivir Limited use to sickest COVID-19 patients

▴ Remdesivir Limited use to sickest COVID-19 patients
Some hospitals said they are still buying the Gilead Sciences medicine to build inventory in case the pandemic accelerates over the winter

U.S. hospitals have turned down about a third of their allocated supplies of the COVID-19 drug remdesivir since July as the need for the costly antiviral wanes, the Department of Health and Human Services (HHS) confirmed on Friday.

Some hospitals said they are still buying the Gilead Sciences medicine to build inventory in case the pandemic accelerates over the winter. But they said current supplies are adequate, in part because they are limiting use to severely ill patients.

The Food and Drug Administration has allowed more liberal remdesivir use, but 6 out of 8 major hospital systems contacted by Reuters said they were not using it for moderate cases.

The slowdown suggests that a shortage of the drug is over and threatens Gilead's efforts to expand the use of remdesivir, which it sells under the brand name Veklury in some countries.

An HHS spokesperson confirmed on Friday that between July 6 and September 8, state and territory public health systems accepted about 72% of the remdesivir they were offered. Hospitals in turn purchased only about two-thirds of what states and territories accepted, as previously detailed to Reuters by Michael Ganio, senior director of pharmacy practice and quality at the American Society of Health-System Pharmacists.

Gilead did not respond to a request for comment.

A surplus of remdesivir - which costs $3,120 for a 6-vial intravenous course - marks a turnaround from earlier in the pandemic, when supplies of the drug had fallen short of demand in some regions.

The government-led distribution of remdesivir will expire at the end of September. Hospitals said they have little information on availability after that.

Remdesivir was first authorized by the FDA in May for emergency use in COVID-19 patients hospitalized and on oxygen support after data showed it helped shorten hospital recovery time.

'Not Impressed'

The agency last month expanded use to hospitalized patients who do not require oxygen support, based on data published in the JAMA medical journal showing that the drug provided a modest benefit for those patients.

The newer data has left many experts unconvinced.

"I am not impressed with the study," said Dr. Adarsh Bhimraj, an infectious disease specialist at the Cleveland Clinic. He said he remains "skeptical" about using remdesivir in patients with moderate COVID-19, especially given the price.

Dr. Rajesh Gandhi, an infectious disease physician at Massachusetts General Hospital in Boston, said his center has stayed focused on using remdesivir for the narrower population of seriously ill patients who need supplemental oxygen.

"No one wants to be in a position of making treatment decisions based on drug availability," he said.

Houston Methodist Hospital is holding off on broader use of remdesivir, and instead is stockpiling it in case of the pandemic flares up in winter - typically the peak season for respiratory illness.

"At this point, we are buying far more than we are using because we are unsure about what will happen at the end of September," said Katherine Perez, infectious disease pharmacist at Houston Methodist.

There is no evidence that COVID-19 patients admitted to the hospital for a day or two due to an underlying health issue, like diabetes or high blood pressure, would benefit from the drug, she added.

Mark Sullivan, associate chief pharmacy officer at Nashville's Vanderbilt University Hospitals & Clinics, said his institution also did not expand remdesivir use based on the newer JAMA data.

"We have kept our treatment protocol the same," he said.

Tags : #COVID-19 #USA #Remdesiver #Gilead

About the Author


Dr. Naila Syed

A well presented, self-motivated, and confident writer. Passionate about educating the masses on medical and nonmedical ways to promote health and lifestyle through my mighty pen.You can write to me at [email protected]

Related Stories

Loading Please wait...
-Advertisements-

Trending Now

Male pattern baldness or Alopecia : What you should know September 18, 2020
China Biopharma plant leak infects thousands with bacterial diseaseSeptember 18, 2020
Alarming rates of transmission of virus in EuropeSeptember 18, 2020
WHO urges safety for health workers September 18, 2020
Moderna to seek COVID vaccine's limited emergency useSeptember 18, 2020
Global Coronavirus cases surpass 30 MillionSeptember 18, 2020
Moderna, Pfizer share COVID-19 vaccine trial blueprints September 18, 2020
UN asks Billionaires for help as 270 Million people face starvationSeptember 18, 2020
UK's COVID-19 test which gives faster results accurateSeptember 18, 2020
AstraZeneca resumes COVID-19 vaccine trials in South AfricaSeptember 17, 2020
Saudi Health Ministry warns against video claiming COVID-19 cureSeptember 17, 2020
Vaccine nationalism puts lives at risk says European Union chiefSeptember 17, 2020
US plans to distribute COVID vaccine immediately after authorizationSeptember 17, 2020
Trump counters CDC chief on vaccine timelineSeptember 17, 2020
A report states half of the vaccines are booked by rich nationsSeptember 17, 2020
Donald Trump on White House staff member testing positiveSeptember 17, 2020
Asian Airlines join trend of scenic flights to nowhere amid pandemicSeptember 17, 2020
Brazil authorizes additional 5,000 volunteers for AstraZeneca COVID-19 vaccineSeptember 17, 2020
China, UAE see positive results in Phase 3 COVID-19 vaccine trialsSeptember 16, 2020
Russia to sell Sputnik-V Vaccine to Dr Reddy's Laboratories September 16, 2020